Mito-TEMPO-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEMito-TEMPOCat.No.:HY-112879CASNo.:1334850-99-5分⼦式:C₂₉H₃₅ClN₂O₂P分⼦量:510.03作⽤靶点:MitochondrialMetabolism;ReactiveOxygenSpecies作⽤通路:MetabolicEnzyme/Protease;Immunology/Inflammation;NF-κB储存⽅式:-20°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性数据体外实验DMSO:125mg/mL(245.08mM;Needultrasonic)H2O:60mg/mL(117.64mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM1.9607mL9.8033mL19.6067mL5mM0.3921mL1.9607mL3.9213mL10mM0.1961mL0.9803mL1.9607mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.25mg/mL(4.41mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥2.25mg/mL(4.41mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.25mg/mL(4.41mM);Clearsolution4.请依序添加每种溶剂：PBSSolubility:50mg/mL(98.03mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY⽣物活性Mito-TEMPO⼀种靶向线粒体的超氧化物歧化酶模拟物，有除超氧化物和烷⾃由的能⼒。体内研究Mito-TEMPO(MT)greatlyattenuatestheincreaseinALTactivitiesandreducestheareasofnecrosisatbothtimepoints,indicatingthattheprotectionbyMito-TEMPOissustaineduntilatleast24hpost-APAP.Mito-TempocouldinducesecondaryapoptosisinthelatephaseofAPAPhepatotoxicity.Mito-TempoinducessecondaryapoptosisafterAPAPoverdosebyinhibitionofRIP3[1].PROTOCOLAnimalMice[1]Administration[1]MaleC57BL/6Jmice(8-12weeks)andRIP3-deficientmice(C57BL/6Nbackground)areusedthroughoutthestudy.Themiceareacclimatedbeforeexperimentswithfreeaccesstodietandwater.Overnight-fastedmice(16-18h)aretreatedi.p.with300mg/kgAPAPdissolvedinwarmsaline.Somemicearetreatedwith200mg/kgAPAPinexperimentsevaluatingeffectofRIP3deficiency.Adoseof20mg/kgMito-Tempodissolvedinsalineisadministeredi.p.1.5or3hafterAPAP.Somemicearesubsequentlytreated(i.p.)with10mg/kgZVDfmkdissolvedinTris-bufferedsalineorvehicle2hafterAPAP.TomimictheclinicalcareofAPAP-overdosepatients,somemicereceivetheantidoteNAC(i.p.,500mg/kg)at1.5or3hafterAPAPoverdose[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.户使⽤本产品发表的科研⽂献•ActaPharmSinB.21July2021.•JHazardMater.15February2022,127268.•BasicResCardiol.2022Aug23;117(1):40.•RedoxBiol.2020Jul;34:101559.•IntJBiolSci.2022Mar6;18(6):2261-2276.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].DuK,etal.Mito-tempoprotectsagainstacuteliverinjurybutinduceslimitedsecondaryapoptosisduringthelatephaseof2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEacetaminophenhepatotoxicity.ArchToxicol.2018Oct15.McePdfHeightCaution:Producthasnotbeenful